Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide-containing TACE versus placebo-containing TACE for primary hepatocellular carcinoma
ChiCTR-TRC-13004604Phase 2Completed
- Sponsor
- First Hospital of China Medical University
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of arsenic trioxide in hepatocellular carcinoma (HCC) (2 arms), sponsored by First Hospital of China Medical University. Primary endpoint: time to progression. Started Jan 2014; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-13004604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13004604.